Saturday, October 25, 2014 Last update: Yesterday, 4:33 PM - Covering Large & Obscure Tech Companies Since 1996

Premier Biomedical Enters Into Discussions with DOD to Initiate Staged Clinical Trials for Possible Head Trauma Cure

Companies mentioned in this article: Premier Biomedical, Inc.

EL PASO, Texas -- (BUSINESS WIRE) -- Premier Biomedical, Inc. (OTCBB: “BIEI”) a biopharmaceutical company focused on developing and commercializing innovative treatment therapies for cancer, traumatic brain injury, Alzheimer’s disease, and other afflictions announced today that they have initiated discussions with William Beaumont Army Medical Center (WBAMC) at Ft. Bliss, TX toward initiating staged clinical trials to treat soldiers suffering from head trauma leading to clinical depression (PTSD) and possible resultant suicide/homicide ideation. This follows and builds on the successful laboratory work completed by the company and its affiliates to date to measure and eliminate specific molecular compounds from cerebral-spinal fluid (CSF) believed to be responsible for these afflictions.

William Hartman, President and CEO of Premier Biomedical stated, “The Department of Defense vetted us and our technology for three years before partnering with Premier Biomedical and the University of Texas at El Paso (UTEP) to work together as a team to solve this pressing problem. The Veterans Administration estimated that one active-duty person per day commits suicide as a result of this problem; counting veterans, this number jumps to almost one suicide per hour, 24 hours per day, 365 days per year! We are excited to take this next further step together involving staged clinical trials to bring us that much closer to developing a cure for those who are suffering the effects of head trauma-related incidents. This has huge potential health ramifications for our soldiers and the American public as a whole, particularly those injured during sports participation.”

About Premier Biomedical, Inc.

Premier Biomedical, Inc. is a research-based company that intends to discover and develop medical treatments for a wide range of diseases in humans, in collaboration with the University of Texas at El Paso and US Department of Defense, initially targeting the treatment of Alzheimer's disease, Traumatic Brain Injury, and Cancer. Premier has licensed the technology behind multiple provisional patents in the United States and a PCT Europe National Patent in the areas of Cancer, Sepsis, and Multiple Sclerosis. Founded in 2010, Premier has partnered with the Department of Defense with Center of Expertise at the William Beaumont Army Medical Center and the University of Texas at El Paso (UTEP). The company's R&D efforts are centered in El Paso, TX and their business offices are in Western Pennsylvania. The Company's common stock trades on the fully reporting Over-The-Counter Bulletin Board under the ticker symbol "BIEI."

Safe Harbor Notice

Certain statements contained herein are "forward-looking statements" (as defined in the Private Securities Litigation Reform Act of 1995). Premier Biomedical, Inc. cautions that statements made in this news release constitute forward-looking statements and makes no guarantee of future performance. Forward-looking statements are based on estimates and opinions of management at the time statements are made. These statements may address issues that involve significant risks, uncertainties, estimates and assumptions made by management. Actual results could differ materially from current projections or implied results. Premier Biomedical, Inc. undertakes no obligation to revise these statements following the date of this news release.

Copyright © Business Wire 2014

Premier Biomedical, Inc.
W. Hartman, 724-633-7033